The diabetic information superhighway has been trafficked lately by news of GlaxoSmithKline’s Avandia, and the recent FDA declaration that the once-promising drug may be more dangerous than previously thought, and may substantially increase the risk of heart problems for patients.
Concern about new drugs is hardly novel, but amidst all this recent news, I can’t help but consider the potentially unforeseen side effects of avant-garde therapeutic agents as I read about them.
Take 11β-HSD1 inhibitors, for example.
Read More